Therapeutic Asset Ratings

748 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
had5-hpv vaccine Oropharynx Squamous Cell Carcinoma	ImmunityBio, Inc.	P2	CCC (53)
Hepatitis B Surface Antigen Cirrhosis Of Liver	Central Hospital, Nancy, France	P2	CCC (53)
Hepatitis B Surface Antigen Hepatitis B Virus Infection	Central Hospital, Nancy, France	P2	CCC (53)
Hepatitis B Surface Antigen Vaccination Failure	Central Hospital, Nancy, France	P2	CCC (53)
Imm-101 Neoplasms Pancreatic	Karen Carty	P2	CCC (53)
JNJ-78436735 Juvenile Dermatomyositis	National Institute of Allergy and Infectious Diseases (NIAID)	P2	CCC (53)
JNJ-78436735 Juvenile Idiopathic Arthritis	National Institute of Allergy and Infectious Diseases (NIAID)	P2	CCC (53)
JNJ-78436735 Multiple Sclerosis	National Institute of Allergy and Infectious Diseases (NIAID)	P2	CCC (53)
JNJ-78436735 Pediatric Multiple Sclerosis	National Institute of Allergy and Infectious Diseases (NIAID)	P2	CCC (53)
JNJ-78436735 Pediatric Systemic Lupus Erythematosus	National Institute of Allergy and Infectious Diseases (NIAID)	P2	CCC (53)
JNJ-78436735 Pemphigus Vulgaris	National Institute of Allergy and Infectious Diseases (NIAID)	P2	CCC (53)
JNJ-78436735 Rheumatoid Arthritis	National Institute of Allergy and Infectious Diseases (NIAID)	P2	CCC (53)
JNJ-78436735 Systemic Lupus Erythematosus	National Institute of Allergy and Infectious Diseases (NIAID)	P2	CCC (53)
JNJ-78436735 Systemic Sclerosis	National Institute of Allergy and Infectious Diseases (NIAID)	P2	CCC (53)
MODERNA COVID-19 VACCINE RNA Juvenile Dermatomyositis	National Institute of Allergy and Infectious Diseases (NIAID)	P2	CCC (53)
MODERNA COVID-19 VACCINE RNA Juvenile Idiopathic Arthritis	National Institute of Allergy and Infectious Diseases (NIAID)	P2	CCC (53)
MODERNA COVID-19 VACCINE RNA Multiple Sclerosis	National Institute of Allergy and Infectious Diseases (NIAID)	P2	CCC (53)
MODERNA COVID-19 VACCINE RNA Pediatric Multiple Sclerosis	National Institute of Allergy and Infectious Diseases (NIAID)	P2	CCC (53)
MODERNA COVID-19 VACCINE RNA Pediatric Systemic Lupus Erythematosus	National Institute of Allergy and Infectious Diseases (NIAID)	P2	CCC (53)
MODERNA COVID-19 VACCINE RNA Pemphigus Vulgaris	National Institute of Allergy and Infectious Diseases (NIAID)	P2	CCC (53)
MODERNA COVID-19 VACCINE RNA Rheumatoid Arthritis	National Institute of Allergy and Infectious Diseases (NIAID)	P2	CCC (53)
MODERNA COVID-19 VACCINE RNA Systemic Lupus Erythematosus	National Institute of Allergy and Infectious Diseases (NIAID)	P2	CCC (53)
MODERNA COVID-19 VACCINE RNA Systemic Sclerosis	National Institute of Allergy and Infectious Diseases (NIAID)	P2	CCC (53)
Monovalent [B.1.351] Cov2 Pres Dtm-As03 Juvenile Dermatomyositis	National Institute of Allergy and Infectious Diseases (NIAID)	P2	CCC (53)
Monovalent [B.1.351] Cov2 Pres Dtm-As03 Juvenile Idiopathic Arthritis	National Institute of Allergy and Infectious Diseases (NIAID)	P2	CCC (53)

Showing 226 to 250 of 748 assets

PreviousPage 10 of 30Next